Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China

Minmin Zhao & Yang Shen et al. · 2023-10-17

Poly (ADP-ribose) polymerase (PARP) inhibitors are a new maintenance therapy option for patients with ovarian cancer (OC). To evaluate the efficacy and influencing factors of the novel PARP inhibitor niraparib for maintenance treatment of Chinese patients with advanced OC. In this retrospective multicenter real-world study patients with advanced OC from 15 hospitals throughout China were enrolled. The primary endpoint was progression-free survival (PFS) and the secondary endpoints included the time to treatment discontinuation and safety. Least Absolute Shrinkage and Selection Operator (LASSO) regression was used to identify possible risk factors for PFS, after which a prediction model was established to evaluate the likelihood of achieving an 18-month PFS. The relationship between the dose of niraparib and PFS was also evaluated. The PFS rates of 199 patients at 6, 12, 18, 24, and 30 months were 87.4%, 75.9%, 63.6%, 56.1%, and 51.8%, respectively. LASSO regression model revealed that only age < 65 years (P = 0.011), BRCA mutations (P < 0.001), and R0 status after cytoreductive surgery (P = 0.01) were significant factors associated with prolonged PFS times. Based on the LASSO logistic regression analysis, a clinical prediction formula was developed: - 2.412 + 1.396Age For Chinese OC patients, niraparib, particularly at a 200 mg individual starting dose, was an effective therapy with easily manageable safety.
Links
DOIPubMed
Journal
Targeted Oncology
Authors
Minmin Zhao, Shanhu Qiu, Xin Wu, Pengcheng Miao, Zhi Jiang, Tao Zhu, Xizhong Xu, Yanling Zhu, Bei Zhang, Donglan Yuan, Yang Zhang, Wei Sun, Aiqin He, Min Zhao, Wenjie Hou, Yingli Zhang, Zhuyan Shao, Meiqun Jia, Mei Li, Jun Chen, Jingcheng Xu, Bingwei Chen, Ying Zhou, Yang Shen
Funding
National Natural Science Foundation of China Grant 82072078Primary Research and Development Plan of Jiangsu Province Grant SBE2020741118Scientific Research Project of Jiangsu Health Commission Grant ZDA2020012National Key Research and Development Program Grant 2022YFC2403400Anhui Provincial Key Research and Development Program Grant 2022e070200132020 USTC Affiliated Hospital Introduction Project to Medical Leading Technology Grant 2020LXJS 05Beijing Science and Technology Innovation Fund Grant KC2021-JX-0186-143